康乐卫士(833575) - 2023 Q4 - 年度业绩预告

Financial Performance - The company expects a net loss attributable to shareholders of 301.27 million yuan for the year 2023, compared to a net loss of 292.82 million yuan in the previous year, indicating a decline in performance [4]. - The primary reason for the expected loss is the ongoing research and development of vaccine products, with no vaccine products having been launched for sale as of December 31, 2023 [5]. Financial Data Integrity - The financial data presented is preliminary and has not been audited by an accounting firm, emphasizing the need for investors to be aware of investment risks [2][6].